Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Schering, Johnson and Johnson VTE drug to surpass that of GSK

Bayer Schering, Johnson and Johnson VTE drug to surpass that of GSK

21st August 2007

Rivaroxabnan, a drug from Bayer Schering and Johnson & Johnson, is set to surpass Arixtra from GlaxoSmithKline (GSK) as the “clinical gold standard” prophylactic treatment for patients with venous thromboembolism (VTE) over the next few years, it has been claimed.

Research from advisory firm Decision Resources claims that improvements and safety and delivery of rivaroxaban over Arixtra will be key in seeing the drug-type overtake GSK’s offering for this indication.

The report – Emerging Oral Anticoagulants Will Challenge Heparin Dominance: A Venous Thromboembolism Study – notes that Arixtra and other anticoagulants require close monitoring and have an unpredictable dose response.

Muneer Ahmad an analyst at Decision Resources, said: “Rivaroxaban will feature improvements in safety and delivery over Arixtra. These areas are important enough to prescribers to make rivaroxaban the gold standard in our model.”

Furthermore, he added that LY-5177 – a compound in development from Eli Lilly – will probably be launched in 2013, with clinical trials suggesting that the drug has an efficacy profile comparable to that of benchmark therapies, while its safety profile exceeds that of rivaroxaban.

Last month, Johnson & Johnson presented positive phase III clinical trial results of rivaroxaban as a preventative treatment for VTE in patients undergoing knee replacement surgery.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.